These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23900371)

  • 1. [Amyloid aggregates: role in Protein Misfolding Disorders].
    Duran-Aniotz C; Moreno-Gonzalez I; Morales R
    Rev Med Chil; 2013 Apr; 141(4):495-505. PubMed ID: 23900371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proteinopathies--forms of neurodegenerative disorders with protein aggregation-based pathology].
    Shelkovnikova TA; Kulikova AA; Tsvetkov FO; Peters O; Bachurin SO; Bukhman VL; Ninkina NN
    Mol Biol (Mosk); 2012; 46(3):402-15. PubMed ID: 22888630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
    Jeffrey M
    Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex proteinopathies and neurodegeneration: insights from the study of transmissible spongiform encephalopathies.
    Piccardo P; Asher DM
    Arq Neuropsiquiatr; 2018 Oct; 76(10):705-712. PubMed ID: 30427511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease.
    Duncan EJ; Cheetham ME; Chapple JP; van der Spuy J
    Subcell Biochem; 2015; 78():243-73. PubMed ID: 25487025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion-Like Protein Aggregates and Type 2 Diabetes.
    Mukherjee A; Soto C
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetes as a protein misfolding disease.
    Mukherjee A; Morales-Scheihing D; Butler PC; Soto C
    Trends Mol Med; 2015 Jul; 21(7):439-49. PubMed ID: 25998900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein misfolding in neurodegenerative diseases.
    Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
    Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration.
    Saxena S; Caroni P
    Neuron; 2011 Jul; 71(1):35-48. PubMed ID: 21745636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the Role of Normal Aging Processes in the Onset and Pathogenesis of Diseases Associated with the Abnormal Accumulation of Protein Aggregates.
    Ilyinsky NS; Nesterov SV; Shestoperova EI; Fonin AV; Uversky VN; Gordeliy VI
    Biochemistry (Mosc); 2021 Mar; 86(3):275-289. PubMed ID: 33838629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could intracrine biology play a role in the pathogenesis of transmissable spongiform encephalopathies, Alzheimer's disease and other neurodegenerative diseases?
    Re RN
    Am J Med Sci; 2014 Apr; 347(4):312-20. PubMed ID: 24185262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy and polyglutamine diseases.
    Jimenez-Sanchez M; Thomson F; Zavodszky E; Rubinsztein DC
    Prog Neurobiol; 2012 May; 97(2):67-82. PubMed ID: 21930185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease.
    Skibinski G; Finkbeiner S
    FEBS Lett; 2013 Apr; 587(8):1139-46. PubMed ID: 23458259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein aggregation diseases: toxicity of soluble prefibrillar aggregates and their clinical significance.
    Stefani M
    Methods Mol Biol; 2010; 648():25-41. PubMed ID: 20700703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aging of the brain, dementias, role of infectious proteins: facts and theories.
    Morinet F
    Interdiscip Top Gerontol; 2014; 39():177-86. PubMed ID: 24862020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
    Naiki H; Nagai Y
    J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegeneration in familial amyloidotic polyneuropathy.
    Gasperini RJ; Small DH
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):680-3. PubMed ID: 21916933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.